Mukesh Rangwani, MD
Psychiatry · Zanesville, OHNPI 1912072646
Payments from drug & device makers
Across 799 payments — averaging $132.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$36K
- Acadia Pharmaceuticals Inc$27K
- Teva Pharmaceuticals USA, Inc.$17K
- AbbVie$14K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Axsome Therapeutics, Inc.$2K
- plus $8K from 27 others
What the payments were for
- Consulting fees$10,85010%
- Speaking & faculty fees$73,28569%
- Travel & lodging$5,4725%
- Food & beverage$16,00415%
- Education$5721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 75 | $36,437 |
| Acadia Pharmaceuticals Inc | 45 | $27,319 |
| Teva Pharmaceuticals USA, Inc. | 85 | $16,792 |
| AbbVie(2 entities) | 152 | $14,036 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $2,502 |
| Axsome Therapeutics, Inc. | 28 | $1,592 |
| Alkermes, Inc. | 64 | $1,572 |
| Takeda Pharmaceuticals U.S.A., Inc. | 86 | $1,196 |
| Neurocrine Biosciences, Inc. | 47 | $1,195 |
| E.r. Squibb & Sons, L.L.C. | 28 | $708 |
| Lundbeck LLC | 52 | $669 |
| Otsuka America Pharmaceutical, Inc. | 30 | $489 |
| Johnson & Johnson | 18 | $321 |
| Idorsia Pharmaceuticals US Inc | 6 | $194 |
| Supernus Pharmaceuticals, Inc. | 3 | $145 |
| Neos Therapeutics, LP | 7 | $132 |
| Jazz Pharmaceuticals Inc. | 1 | $126 |
| Lilly USA, LLC | 1 | $122 |
| Harmony Biosciences LLC | 1 | $113 |
| Tris Pharma Inc | 7 | $103 |
| Corcept Therapeutics | 1 | $86 |
| Vanda Pharmaceuticals Inc. | 2 | $61 |
| Ironshore Pharmaceuticals Inc. | 3 | $45 |
| Alpha Cognition USA, Inc. | 1 | $44 |
| Corium, LLC | 2 | $35 |
| Indivior Inc. | 2 | $27 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
| Biogen | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,183 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 76 | $243,134 |
| IngrezzaValbenazine Tosylate | 11 | $92,897 |
| Austedo XrDeutetrabenazine | 19 | $79,980 |
| VraylarCariprazine Hcl | 26 | $36,571 |
| TrintellixVortioxetine Hydrobromide | 36 | $21,894 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $19,864 |
| Effexor XrVenlafaxine Hcl | 12 | $14,727 |
| Lurasidone Hcl | 11 | $13,423 |
| Quetiapine Fumarate | 348 | $10,814 |
| Duloxetine Hcl | 514 | $8,229 |
| Chlorpromazine Hcl | 14 | $7,714 |
| Aripiprazole | 205 | $6,582 |
| StratteraAtomoxetine Hcl | 14 | $5,779 |
| Trazodone Hcl | 566 | $4,819 |
| Alprazolam | 643 | $4,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $27,319 | $243,13476 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,195 | $92,89711 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $16,792 | $79,98019 claims |
| AbbVieVraylar | $14,036 | $36,57126 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,196 | $21,89436 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $36,437 | $19,86414 claims |
| Lilly USA, LLCOlanzapine | $122 | $4,626124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Zanesville
- Ajay SharmaZanesville$446K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.